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Attention deficit hyperactivity disorder (ADHD) is a common 
developmental disorder characterized by impulsivity, inattention, and 
hyperactivity.  In rodents, neonatal 6-OHDA lesions is an established model of 
ADHD because it produces symptoms of hyperactivity and cognitive deficits that 
improve following psychostimulant treatment.  Recently, early alcohol exposure 
in rodents has also been suggested as a model of ADHD due to the high 
prevalence of ADHD in children exposed prenatally to alcohol. However, children 
exposed to prenatal alcohol differ in symptoms from children with idiopathic 
ADHD, suggesting that ADHD caused by prenatal alcohol exposure may be a 
special subtype of ADHD or a completely different disorder. The aim of the 
present study was to compare the 6-OHDA lesion model with the effects of early 
alcohol exposure on hyperactivity, psychostimulant response, and passive 
avoidance learning in preweanling rats. It was hypothesized that alcohol 
exposure and the combined effects of a 6-OHDA lesion and exposure to alcohol 
would result in increased locomotor hyperactivity and poorer performance on the 
passive avoidance task. A total of 1,053 male and female Sprague-Dawley rats 
were lesioned with 6-OHDA or placed in a lesion control group on postnatal day 
(PD 3). Beginning on PD 4, rats were exposed to alcohol (0, 0.3, or 3 g/kg) for six 
consecutive days or were unhandled.  On PD 19, rats were habituated to a 
locomotor chamber for 60 min. On the following day (PD 20), the rats were 
injected with amphetamine (1 mg/kg), methylphenidate (2.5 mg/kg) or saline and 
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locomotor activity was measured for 60 min. On PD 23, a separate group of rats 
were trained on a passive avoidance task and retention was tested for three 
consecutive days. Our results demonstrated that exposure to a low dose of 
alcohol can cause an increase in the locomotor activity of female rats, while 
exposure to a high dose of alcohol can disrupt memory. In addition, our results 
indicated that 6-OHDA lesions and alcohol exposure do not have an additive 
effect. In summary, these data suggest neonatal alcohol can cause a dose 
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 Attention Deficit Hyperactivity Disorder (ADHD) is a highly prevalent 
disorder affecting children regardless of socio-economic background or ethnicity. 
ADHD was initially known as “hyperkinetic disorder of childhood” and is found 
predominantly in males (Curatolo, D'Agati, & Moavero, 2010; Kiely, 2015). A 
recent systematic review and meta-analysis estimated that approximately 7% of 
children worldwide, under the age of 18, meet the diagnostic criteria for ADHD 
(Thomas, Sanders, Doust, Beller, & Glasziou, 2015). 
 The three core symptoms of ADHD, inattention, hyperactivity, and 
impulsivity, correspond with the clinical presentations of the disorder: Inattentive, 
hyperactive-impulsive, and combined type (Baumeister, Henderson, Pow, & 
Advokat, 2012). Symptomology of ADHD can vary across settings, such as in the 
home, school, and workplace (Kiely, 2015; Russell, 2011). In the inattentive 
presentation, the individual has difficulty staying focused, is disorganized, has 
difficulty following instructions or conversations and is forgetful. The symptoms of 
hyperactive-impulsive presentation include fidgeting, impulsivity, and disruption 
of others. In the combined presentation the reported symptoms are a blend of 
inattentive and hyperactive-impulsive (American Psychiatric Association, 2013). 
 ADHD is defined as a disruptive neurobehavioral disorder, because it is 
associated with academic struggles, socialization issues, and increased criminal 
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behavior (Punja et al., 2016; Watts, 2018).  The symptoms of ADHD are 
excessive, pervasive, and persistent in that the behaviors are extreme, show up 
in multiple settings, and can be long-term. ADHD is often comorbid with other 
disorders, such as oppositional defiant disorder, major depressive disorder, and 
anxiety (Sharma & Couture, 2014; Watts, 2018). 
 Currently, there is no screening test available to detect ADHD nor is there 
a cure; thus, only treatment is available for individuals with ADHD. Treatments for 
ADHD include behavioral therapy, dietary restrictions, and pharmacological 
intervention (Shier, Reichenbacher, Ghuman, & Ghuman, 2013). 
Psychostimulant compounds, such as methylphenidate and amphetamine, are 
recommended as the first-line of treatment for ADHD (Chung, Tchaconas, 
Meryash, & Adesman, 2016; Shier et al., 2013). For the 30% of ADHD patients 
not suitable for psychostimulants there are alternative options, such as 
atomoxetine and α-2 agonists (Curatolo et al., 2010; Kiely, 2005). Stimulant and 
non-stimulant treatments are effective; however, a number of concerns involving 
long-term effects are still unanswered. 
Neurobiology of ADHD 
 The etiology and pathophysiology of ADHD are not yet completely 
understood, but a number of structural, functional, neurochemical, and genetic 
abnormalities in the brains of individuals with ADHD have been identified. 
Magnetic resonance imaging (MRI) studies have reported smaller anatomical 
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areas and volumes in patients with ADHD (Castellanos et al., 2002). There is a 
reduction in total brain size in children with ADHD that persists into adolescence 
and their brain volumes are decreased by 3% when compared to controls 
(Castellanos et al., 2002; Tripp & Wickens, 2009). Cortical thinning is a robust 
neuroanatomical marker for ADHD in childhood and adolescence (Narr et al., 
2009; Shaw et al., 2006; Tripp & Wickens, 2009) and the rate at which cortical 
thinning occurs is correlated with the severity of hyperactivity and impulsivity 
(Shaw et al., 2011). 
 A review of neuroimaging studies involving individuals with ADHD 
indicates that the prefrontal cortex (PFC), caudate, and cerebellum are the 
primary brain regions showing reduced volumes (Sharma & Couture, 2014). 
These reductions may be of importance, because these regions are involved in 
cognitive processing, attention, emotion, and behavior regulation (Sharma & 
Couture, 2014). In addition, neuroimaging studies on children with ADHD found 
reductions of the amygdala, thalamus, hippocampus, cerebellar vermis, splenium 
of the corpus callosum, as well as abnormal asymmetry of the caudate nucleus 
and the pallidum (Kasparek, Theiner, & Filova, 2015; Tripp & Wickens, 2009). 
Asymmetry of the caudate is related to severity of attention deficits (Schrimsher, 
Billingsley, Jackson, & Moore, 2002). 
 A recent meta-analysis of functional magnetic resonance imaging (fMRI) 
studies showed consistent differences between individuals with and without 
ADHD in two distinct domains: inhibition and attention. Abnormalities of inhibition 
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were related to the right hemispheric fronto-basal ganglia networks, including the 
inferior frontal cortex, supplementary motor area, and anterior cingulate cortex 
(Hart, Radua, Nakao, Mataix-Cols, & Rubia, 2013). In the attention domain, the 
areas exhibiting reduced activity were the dorsolateral prefrontal cortex (DLPFC) 
and cerebellar areas (Hart, et al., 2013; Kasparek et al., 2015). Furthermore, Hart 
et al. (2013) reported a different pattern of brain dysfunction during inhibition 
tasks in children and adults with ADHD. Specifically, hypoactivation of the 
supplementary motor area and basal ganglia was present in children, while 
hypoactivation of the inferior frontal cortex and thalamus was detected in adults.  
 Neurochemical theories of ADHD have been around since at least 1970 
(Baumeister et al., 2012). Dysfunction of monoamine systems is suspected, 
because the fronto-subcortical circuits associated with ADHD are rich in 
catecholamines, and the most effective drugs used to treat ADHD are 
psychostimulants that block dopamine (DA) and norepinephrine (NE) 
transporters (Curatolo et al., 2010; Sagvolden, Russell, Aase, Johansen, & 
Farshbaf, 2005). Furthermore, functional activation studies on individuals with 
ADHD show that long-term treatment with stimulant medication is associated with 
normalization of caudate activity (Hart et al., 2013). 
 ADHD has a complex etiology, and multiple genetic factors are thought to 
play an important role. Numerous studies have found a strong familial genetic 
contribution, with the heritability rate estimated at 76% (Curatolo et al., 2010; 
Shier et al., 2013; Tripp & Wickens, 2009). Twin studies have also demonstrated 
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high heritability of approximately 0.80 (Kieling, Goncalves, Tannock, & 
Castellanos, 2008). No single gene yet discovered plays a major role, but gene 
associations have been found (Shier et al., 2013; Tripp & Wickens, 2009). The 
genes that may be involved are those coding for D4 (DRD4) and D5 receptors 
(DRD5), the DA transporter (DAT1), the norepinephrine transporter (NET1), 
synaptosomal-associated protein 25 (SNAP-25), the serotonin transporter 
(5HTT), and the serotonin 1B receptor (HTR1B) (Russell, 2011; Sharma & 
Couture, 2014; Tripp & Wickens, 2009). In rodent brains, the SRY gene is highly 
expressed in areas that contain dense populations of dopaminergic neurons, 













 ADHD can be treated effectively with pharmacological agents, behavioral 
therapies, and a combination of both. Psychostimulants are the most widely used 
treatment for ADHD and have been used for over 50 years. Psychostimulant 
treatment is associated with improved academic achievement in school and 
improved quality of life (Shier et al., 2013).  Currently, an estimated 2.8 million 
children in the United States take psychostimulants for ADHD (Baumeister et al., 
2012; Shier et al., 2013). 
 The two most commonly prescribed psychostimulants for the treatment of 
ADHD are methylphenidate (MPH) and amphetamine (AMP). These 
psychostimulants work by increasing synaptic levels of NE and DA, are available 
in immediate or extended release forms, and are efficacious for short- and long-
term use (Punja et al., 2016; Shier et al., 2013). Common adverse effects of 
stimulant medications include loss of appetite, stomachache, insomnia, and 
headaches (Shier et al., 2013). Unusual side-effects include tics, irritability, and 
increased heart rate and blood pressure. A majority of long-term follow-up 
studies on stimulant medications did not find an increased risk for substance use, 
abuse, or dependence in adulthood (Shier et al., 2013). 
 Amphetamine increases the availability of NE and DA in the synaptic cleft 
by stimulating release and inhibiting re-uptake and metabolism (Shier et al., 
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2013). A common formulation of AMP is Adderall (Sharma & Couture, 2014). In 
contrast, MPH works by blocking the DAT and NET transporters (Curatolo et al., 
2010). MPH increases extracellular levels of DA in the prefrontal cortex, nucleus 
accumbens, and caudate nucleus (Kasparek et al., 2015). Some of the brand 
names for MPH include Ritalin, Concerta, and Methylin (Sharma & Couture, 
2014). Although their clinical effects are qualitatively similar, MPH has milder side 
effects than AMP. MPH has a half-life of about 2 hours versus AMP’s half-life of 7 
to 30 hours (Baumeister et al., 2012). Furthermore, MPH is less likely to produce 
psychosis and other side effects (Baumeister et al., 2012).  
 Because of their efficacy, psychostimulants are considered first-line 
agents for the treatment of ADHD (Shier et al., 2013). However, non-stimulant 
medications are an important second option for treating ADHD. Typically, these 
compounds are only used after the first-line agents have exhibited a poor 
response or cannot be used (Sharma & Couture, 2014; Shier et al., 2013). Non-
stimulants possess inferior efficacy compared to psychostimulants, but their side 
effects are generally milder (Shier et al., 2013). Importantly, non-stimulants do 
not have the same abuse potential as stimulants. The second-line medications 
for the treatment of ADHD include atomoxetine, bupropion, α-2 agonists, and 
tricyclic antidepressants (Sharma & Couture, 2014; Shier et al., 2013). Since 
most of these second-line medications are seldom prescribed there is inadequate 
empirical information regarding efficacy and safety of higher doses (Shier et al., 
2013). 
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 Atomoxetine (ATX) is a potent selective norepinephrine reuptake inhibitor 
that works by enhancing DA and NE transmission in cortical and subcortical 
areas, but has limited actions in the striatum (Curatolo et al., 2010; Sharma & 
Couture, 2014; Shier et al., 2013). ATX promotes attention and executive 
functioning in ADHD individuals (Curatolo et al., 2010). ATX is the most favorable 
of the non-stimulants because of its safety and efficacy (Himpel, Banaschewski, 
Heise, & Rothenberger, 2005). ATX reduces tics and anxiety, thus it can serve as 
a good alternative for ADHD individuals with these comorbidities (Sharma & 
Couture, 2014). 
 Bupropion has a similar mechanism of action as both psychostimulants 
and ATX, as bupropion inhibits the reuptake of DA and NE (Sharma & Couture, 
2014). Bupropion is available in immediate and extended release form, but due 
to its short half-life a twice daily administration is recommended (Sharma & 
Couture, 2014). This pharmacological agent improves the ADHD symptom of 
hyperactivity (Shier et al., 2013). FDA warnings of increased risk of suicidal 
thoughts and behaviors are applicable to bupropion, since it is classified as an 
antidepressant (Waxmonsky, 2005).  
 The immediate release α-2 agonists, guanfacine and clonidine, were 
initially used off-label, until the FDA approved their use for the treatment of 
ADHD in an extended release form (Sharma & Couture, 2014). These α-2 
agonists stimulate presynaptic and postsynaptic α2 receptors resulting in 
improved cognitive functioning in individuals with ADHD (Sharma & Couture, 
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2014). Guanfacine, a selective α-2 agonist, strengthens the functional 
connectivity of prefrontal cortex networks, resulting in improved working memory 
(Curatolo et al., 2010). Clonidine, a nonspecific α-2 agonist, is more effective at 
reducing symptoms of hyperactivity and impulsivity than symptoms of 
inattentiveness (Waxmonsky, 2005). A common side-effect of clonidine is 
sedation, which limits its daytime use (Waxmonsky, 2005). Unlike the previously 
mentioned pharmacological agents, gradual withdrawal from α-2 agonists is 
suggested to prevent potential risks associated with their actions as 
antihypertensive agents (Shier et al., 2013). 
 The least preferred non-stimulant treatment for ADHD are the tricyclic 
antidepressants (TCAs), because they have a wide range of negative side-
effects and drug interactions (Pliszka, 2003; Sharma & Couture, 2014). Until 
concerns surfaced involving sudden death, TCAs were the primary second-line 
treatments for ADHD (Pliszka, 2003). TCAs, like imipramine, are effective for 
treating hyperactivity, but are only used when stimulants or alternative agents 
prove ineffective (Himpel et al., 2005). TCAs may also be a reasonable 
alternative for ADHD individuals who experience tics (Pliszka, 2003). Gradual 
tapering off from these non-stimulants is recommended, due to the potential of 
side-effects (Waxmonsky, 2005). 
 A fairly new, but promising, stimulant is modafinil, which was initially 
approved for the treatment of narcolepsy (Shier et al., 2013; Waxmonsky, 2005). 
The mechanism of action of this drug is not yet fully understood, but it is known 
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to affect DA, NE and histamine (Shier et al., 2013). Modafinil has been used off-
label to treat ADHD symptoms and has been found to be effective in a few 
studies (Biederman & Pliszka, 2008). The common side-effects of modafinil are 

















RODENT MODELS OF ADHD 
 Animal models have proven useful for understanding the cause of human 
disorders and in developing treatments. To be useful, these models must 
possess face validity, construct validity, or predictive validity (Russell, 2011). 
Face validity refers to the animal model being able to mimic the fundamental 
symptoms of the human disorder. Construct validity refers to the model having 
similar etiology and underlying pathophysiological mechanisms. Lastly, models 
that have predictive validity should display symptom to the same treatments 
given to the clinical population, provide insight into the underlying mechanisms of 
the disorder, as well as predict biological and behavioral aspects of the disorder 
that are yet to be observed in clinical evaluations (Russell, 2011). In short, animal 
models that are similar in terms of etiology, biochemistry, symptomatology, and 
treatment are the most useful (Sagvolden et al., 2005). 
 The most thoroughly studied animal model of ADHD is the spontaneously 
hypertensive rat (SHR) bred from the Wistar Kyoto control rat strain (WKY) 
(Russell, 2011; Sagvolden et al., 2005). SHRs exhibit poor performance in visual 
discrimination tasks that require sustained attention, they display impulsivity 
during the extinction phase of an operant task, and hyperactivity is evident by 
their increased response rates in free operant tasks and increased locomotor 
activity in an open field (Russell, 2011; Sagvolden et al., 2005; Stanford & 
Tannock, 2011). Similar to the neuropathology of children with ADHD, SHR rats 
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have reduced brain volumes in the prefrontal cortex, occipital cortex, and 
hippocampus. Moreover, there are fewer neurons in these brain areas when 
compared to controls rats (Russell, 2011; Sagvolden et al., 2005). Dysfunction of 
the DA and NE neurotransmitter systems are observed in this model (Sagvolden 
et al., 2005). The SHR model has predictive validity, because medications used 
to treat ADHD, such as MPH, AMP, and guanfacine improve behavioral deficits 
(Stanford & Tannock, 2011). Even though this model displays numerous 
behavioral characteristics similar to those observed in humans with ADHD, the 
usefulness of the model has been criticized by a confounding factor of 
hypertension, however hypertension does not develop until adulthood (Russell, 
2011; Sagvolden et al., 2005). 
 A transgenic rodent model of ADHD, the DAT knock-out (DAT-KO) mouse 
model, is also extensively studied. While the genetic basis of ADHD is not fully 
understood, neurobiological evidence on the etiology of ADHD provides insight 
into plausible genes that are involved. This rodent model is used to study the 
absence of the gene that codes for DAT-1, which is responsible for synaptic DA 
uptake (Sagvolden et al., 2005). The DAT-KO model provides useful information 
on the neurobiological consequences of reduced midbrain DAT (Russell, 2011). 
DAT-KO mice exhibit impulsivity and impairments on learning and memory tasks 
(Stanford & Tannock, 2011; Sagvolden et al., 2005). DAT-KO mice are three to 
five times more hyperactive than controls, possibly due to elevated extracellular 
DA levels within the striatum (Sagvolden et al., 2005; Stanford & Tannock, 2011). 
 13 
Psychostimulants (e.g., MPH and AMP) attenuate hyperactivity in DAT-KO mice, 
but extracellular DA concentrations are unchanged (Gainetdinov, Caron, & 
Lombroso, 2001). These results suggest that non-dopaminergic systems are 
involved in the modulation of locomotor activity in the DAT-KO mice model. While 
a selective NE transporter inhibitor, nisoxetine, has no effect on the hyperactivity 
of DAT-KO mice, the selective serotonin reuptake transporter (SERT) inhibitor, 
fluoxetine, does reduce hyperactivity in this ADHD model (Gainetdinov et al., 
2001; Stanford & Tannock, 2011). DAT-KO mice provide convincing evidence 
that the hyperactivity induced by elevated DA levels can be reduced by drugs 
that activate the serotonergic system (Gainetdinov et al., 2001). 
 Environmentally-induced models of ADHD involve the application of an 
exogenous manipulation, such as a toxin or trauma, to induce ADHD-like 
phenotypes. In neonatal rats, anoxia causes permanent neurochemical 
abnormalities in monoamine systems, along with hyperactivity and spatial 
memory impairment (Puumala et al., 1996; Russell, 2011; Sagvolden et al., 
2005). Furthermore, amphetamine attenuated hyperactivity in the anoxia model, 
thus supporting its use as an animal model of ADHD (Kostrzewa et al., 2008). 
ADHD resulting from anoxia lacks construct validity and, hence, has not gained 
popularity for the study of ADHD.  
 One of the most commonly-utilized ADHD models is the neonatal 6-
hydroxydopamine (6-OHDA) rat model. Administering an intracranial injection of 
6-OHDA in neonatal rats causes selective and permanent DA depletion (Stanford 
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& Tannock, 2011). This selective chemical lesion model has a phenotypic 
resemblance to ADHD, because rats express hyperactivity and inattention, but 
not impulsivity (Russell, 2011; Sagvolden et al., 2005; Stanford & Tannock, 
2011). Neonatal 6-OHDA lesioned rats also display impaired learning in spatial 
discrimination tasks (Russell, 2011). The neonatal 6-OHDA-lesioned rat has face 
and predictive validity (Sagvolden et al., 2005; Stanford & Tannock, 2011). This 
model has permitted the evaluation and prediction of the efficacy of new ADHD 
therapies (Caballero et al., 2011). For example, both AMP and MPH reduce the 
hyperactivity of neonatal 6-OHDA lesioned rats. Findings from these studies 
suggest that the therapeutic effects of AMP and MPH may not be mediated 
through the DA system, but rather through NE and SE transmission (Stanford & 
Tannock, 2011; Russell, 2011). 
  A comparatively new pharmacological model of ADHD involves prenatal 
alcohol exposure (PAE). In humans, PAE has been linked to impairments in 
learning and memory, with ADHD being a common diagnosis (Marquardt & 
Brigman, 2016; Patten, Fontaine & Christie, 2014; Rojas-Mayorquin et al., 2016). 
Although prenatal alcohol treatment is not the typical method for modeling 
ADHD, it is still representative because it has face and predictive validity 
(Kostrzewa et al., 2008). The PAE model has face validity because rats exhibit 
impulsivity, hyperactivity, and cognitive deficits, such as delays in learning and 
memory, that are comparable to humans with ADHD (Atalar, Uzbay & Karakaş, 
2016; Kostrzewa et al., 2008; Russell, 2011). PAE rats demonstrate reduced cell 
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numbers in layers II and V of the medial prefrontal cortex and cerebellar cortex, 
which likely results in the learning deficits. PAE rats also have neurochemical 
deficits involving catecholamine, indolamine, and amino acid neurotransmitters, 
similar to those observed in ADHD (Atalar et al., 2016; Rojas-Mayorquin et al., 
2016). The PAE model has predictive validity because the psychostimulant MPH 
normalizes VTA DA neuron activity (Choong & Shen, 2004). In all, this animal 
model mimics the behavioral, neuroanatomical, and 
















 Ethanol is the alcohol found in commonly consumed alcoholic beverages. 
When ingested, alcohol acts as a central nervous system (CNS) depressant 
(Roberto & Varodayan, 2017). Excessive alcohol use can result in a wide range 
of behavioral and health problems, such as cardiovascular diseases, liver 
cirrhosis, cancer, depression, and motor vehicle accidents (Liang & Olsen, 2014; 
Tan et al., 2015). The consumption of alcohol in excess is the third leading cause 
of preventable death in the United States, as reported by the Centers for Disease 
Control and Prevention (CDC) (Liang & Olsen, 2014). An estimated 18 million 
Americans over the age of 18 suffer from alcohol use disorders (AUD), creating a 
substantial public health problem (Liang & Olsen, 2014; Roberto & Varodayan, 
2017). 
Alcohol Pharmacology 
 The pharmacodynamics of alcohol are complex, due to the various 
neurotransmitter systems involved (Koob, 2004). Some of the systems known to 
be affected by alcohol consumption include serotonin, GABA, and glutamate. 
There is well-established evidence that alcohol alters 5-HT function with the most 
consistent finding being potentiation of 5-HT3 receptor function (Banerjee, 2014; 
Lovinger, 1999). Alcohol acts pre-synaptically at the GABA neuron to increase 
GABA release and acts post-synaptically to enhance GABA receptor action 
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(Banerjee, 2014; Koob, 2004). Alcohol increases GABA receptor action by 
allowing more CI- to enter at the GABAA receptor, this results in inhibitory 
postsynaptic potential (Davies, 2003; Koob, 2004). Alcohol also inhibits 
glutamate activity in the brain. This decrease in glutamate transmission is 
thought to be mediated via NMDA receptors (Banerjee, 2014; Koob, 2004). 
 Most of the alcohol consumed is metabolized in the liver (Zakhari, 2006). 
The most common pathway involves alcohol dehydrogenase (ADH). ADH 
metabolizes alcohol to acetaldehyde, which in turn, is converted to acetic acid in 
the presence of aldehyde dehydrogenase (ALDH). Acetic acid is then oxidated to 
carbon dioxide and water (Eberhart & Parnell, 2016; Zakhari, 2006). Although 
ADH mediates the majority of the biotransformation of alcohol to acetaldehyde, 
cytochrome P450 2E1 (CYP2E1) and catalase can also metabolize alcohol 
(Eberhart & Parnell, 2016; Zakhari, 2006). 
Prenatal Alcohol Exposure 
 The consumption of alcohol by pregnant women is particularly 
problematic. A nationwide telephone survey by the Behavioral Risk Factor 
Surveillance System (BRFSS) revealed that among women alcohol use is at 
53.6% (Tan et al., 2015). The same poll indicated that the prevalence of alcohol 
use by pregnant women was 10.2% (Tan et al., 2015). Interestingly, pregnant 
women aged 35-44 and those with college degrees reported a higher rate of 
alcohol use than other age groups and less educated women (Tan et al., 2015). 
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 Prenatal alcohol exposure (PAE) occurs when a woman drinks alcohol 
while pregnant. The teratogenic effects of maternal ingestion of alcohol during 
pregnancy has been observed in both human and animal populations (Cronise et 
al., 2001). Numerous developmental, cognitive, and behavioral problems, 
ranging from mild to severe, can occur from PAE (Gupta et al., 2016; Hausknecht 
et al., 2005). The first disorder recognized to result from prenatal alcohol use was 
fetal alcohol syndrome (FAS). This syndrome is characterized by facial 
abnormalities, growth deficits, both prenatally and postnatally, as well as CNS 
dysfunction (Thomas, Warren, & Hewitt, 2010). Because PAE produces such a 
wide range of effects, and not all cases meet the diagnostic criteria for FAS, 
there is now the umbrella term of fetal alcohol spectrum disorder (FASD) in 
addition to FAS (Thomas et al., 2010). 
 FASD encompasses the broad range of impairments that can occur from 
in utero alcohol exposure, such as deficits in intellectual performance, executive 
function, learning and memory, language, sensory function, motor function, 
behavior, and secondary disabilities including depression and anxiety (Hellemans 
et al., 2010; Mattson et al., 2011; Schneider, Moore, & Adkins, 2011; Wetherill et 
al., 2018). FASD includes partial FAS, which describes some but not all signs 
and symptoms of FAS. FASD also includes alcohol-related birth defects (ARBD), 
this being PAE-induced physical abnormalities. Lastly, FASD also includes 
alcohol-related neurodevelopmental disorder (ARND), which incorporates 
alcohol-induced impairments of growth and development of the CNS as well as 
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cognitive and behavioral problems without facial or growth deformities (Thomas 
et al., 2010). A recent meta-analysis of FASD reported a prevalence rate of 33.5 
per 1,000 births in the United States (Wetherill et al., 2018). Because of the 
lifelong consequences of PAE, it is considered to be a major social and economic 
burden (Wetherill et al., 2018). 
 Rodent models are ideal for studying the effects of alcohol on 
development, because rodent studies examining PAE show similar effects to 
those observed in humans. In an MRI study, the brain images of mice and 
humans exposed to comparable amounts of prenatal correspond well with each 
other. For example, mice given a moderate dose of alcohol showed thinning of 
the corpus collosum, similar to a child with partial FAS, while mice exposed to a 
large dose of alcohol exhibited a severe reduction of the corpus collosum and 
damage to the hippocampal commissure (O’Leary-Moore et al., 2011). Rodent 
studies assessing the effects of PAE have also demonstrated impairments in 
behavioral and cognitive function, including learning and memory deficits, 
hyperactivity, hyper-responsivity to stressors, as well as deficits in both response 
inhibition and the appropriate use of environmental cues, which are similar to 
those observed in children with FASD (Cronise et al., 2001; Hellemans et al., 
2010; Schneider et al., 2011).  
 In humans and animals, a number of risk factors influence the 
teratogenicity of alcohol and the probability of fetal alcohol-related effects. These 
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risk factors are exposure pattern, dose, stress, environmental influences and 
certain genetic variants (Schneider et al., 2011; Sulik, 2014). Due to the delicate 
process of neurogenesis, the timing of alcohol exposure in relation to the 
developing neural system can profoundly affect neuronal outcomes (Schneider et 
al., 2011). FASD research conducted in rodents has determined that the first and 
third trimesters are the most vulnerable periods for alcohol-induced 
neuroteratogenesis (Dursun et al., 2006; Schneider et al. 2011; Sulik, 2014). 
Environmental factors that may interact with and exacerbate the effects of 
alcohol exposure include exposure to other drugs, maternal nutrition, and 
obstetric complications (Russell, 2011).  
 The gene-alcohol interactions underlying FASD are not yet well 
understood. Genes from the alcohol dehydrogenase (ADH) family have been 
investigated for a potential genetic link with FASD. Investigations of human gene 
alcohol interactions have focused on the major alcohol metabolizing enzyme, 
ADH1 (Eberhart & Parnell, 2016; Gupta et al., 2016). This family has 3 loci: 
ADH1A, ADH1B, and ADH1C. Data from these investigations have produced 
contradictory results as to whether the ADH1B*3 allele works as a protective 
mechanism or induces susceptibility to FASD. The ADH1B*3 allele clears alcohol 
rapidly suggesting a protective mechanism (Neumark et al., 2004). Additionally, 
maternal genotypes with at least one ADH1B*3 allele correlated with a lower rate 
of FASD (Gupta et al., 2016). In contrast, mothers with an ADH1B*1/ADH1B*3 
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GABA & GLUTAMATE 
 The amino acid -aminobutyric acid (GABA) is an important 
neurotransmitter in the regulation of brain neuronal activity. GABA is one of the 
earliest expressed neurotransmitters during ontogeny. It is detectable during the 
embryonic stage and is present throughout the lifespan (Wang & Kriegstein, 
2009). During embryonic development, GABA acts in an excitatory manner and 
is implicated in neurogenesis (Allen et al., 2015; Wang & Kriegstein, 2009; Wu & 
Sun, 2015). As the brain matures, GABA’s function switches from excitatory to 
inhibitory (Allen et al., 2015; Wang & Kriegstein, 2009; Wu & Sun, 2015). GABA 
and the excitatory neurotransmitter glutamate modulate the inhibitory-excitatory 
balance necessary for proper brain function (Allen et al., 2015; Wu & Sun, 2015). 
The imbalance of either GABA or glutamate can result in several pathologies, 
including anxiety, depression, and schizophrenia (Allen et al., 2015; Wu & Sun, 
2015). 
GABA Synthesis, Release, and Catabolism 
 GABA is synthesized from glutamate via the enzyme glutamate 
decarboxylase (GAD) (Wong, Bottiglieri & Snead, 2003). Once synthesized, 
GABA is packaged into vesicles by vesicular GABA transporters (VGAT). When 
the presynaptic neuron is depolarized it releases GABA into the synaptic cleft via 
calcium dependent exocytosis (Wong et al., 2003; Wu & Sun, 2015). After 
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release, GABA is removed from the cleft by GABA transporter proteins (GATs) 
(Wu & Sun, 2015). GABA is metabolized by GABA transaminase to form succinic 
semialdehyde (Wong et al., 2003). Succinic semialdehyde is then oxidized by 
succinic semialdehyde dehydrogenase to succinate (Ravasz et al., 2017). 
Glutamate Synthesis, Release, and Catabolism 
 Glutamate is a non-essential amino acid that serves as the major 
excitatory neurotransmitter of the nervous system (Yelamanchi et al., 2016). 
Within the presynaptic terminal, glutamate is synthesized from glutamine by 
glutaminase (Hertz, 2011; Meyer & Quenzer, 2005; Yelamanchi et al., 2016). 
Three different vesicular glutamate transporters move glutamate into synaptic 
vesicles: VGLUT1, VGLUT2, and VGLUT3 (Zhou & Danbolt, 2014). Synaptic 
release of glutamate occurs from nerve terminals by exocytosis in synaptic 
vesicles (Zhou & Danbolt, 2014). Once released into the synaptic cleft, glutamate 
activity can be terminated by uptake via high affinity transporters located in glial 
cells and presynaptic terminals (Meyer & Quenzer, 2005). The glutamate taken 
back into glial cells is converted into glutamine via glutamine synthetase and 
reintroduced in the glutamine–glutamate cycle (Hertz, 2013; Meyer & Quenzer, 
2005). 
GABA Receptors 
 GABA stimulates two receptor subtypes GABAA and GABAB, both of which 
contribute to the long-term inhibition of synaptic transmission (Banerjee, 2014). 
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These receptors differ from one another in structure, function, and sequence. 
GABAA has 13 ionotropic receptor subunits (α1-6, β1-3, γ1-3 and δ) and is 
considered a fast-synaptic inhibitory receptor (Allen et al., 2015; Sigel & 
Steinmann, 2012; Wong et al., 2003; Wu & Sun, 2015). When activated, GABAA 
receptors allow CI- into the cell membrane (Allen et al., 2015). High densities of 
GABAA receptors are found in the limbic system, retina, and spinal cord (Allen et 
al., 2015). In contrast, GABAB receptors are metabotropic (Sigel & Steinmann, 
2012; Wong et al., 2003; Wu & Sun, 2015). GABAB receptors have two subtypes: 
GABAB1 and GABAB2 (Wu & Sun, 2015). GABAB receptors are slow synaptic 
inhibitors that regulate K+ and Ca2+ channels via a G-protein mediated 
mechanism (Allen et al., 2015; Koob, 2004; Wong et al., 2003; Wu & Sun, 2015). 
GABAB receptors are primarily found in the thalamus, hippocampus, and 
cerebellum (Allen et al., 2015; Padgett & Slesinger, 2010; Wu & Sun, 2015). 
Ontogeny of GABA Receptors 
 GABAA receptors have a complex pattern of development, in situ 
hybridization of tissue sections in rodents reveals differences in the pattern of 
expression across ontogeny. In Purkinje cells, 1, 2, 3 and 2 are persistently 
expressed from birth to adulthood (Laurie, Wisden, & Seeburg, 1992; Ma et al., 
1993; Zdilar et al., 1992). In the cortex and thalamus, expression of subunits 2, 
3, 5 and 3 is noted in both embryonic and early postnatal period (Laurie et 
al., 1992; Simeone, Donevan, & Rho, 2003). In the spinal cord, subunits 4 and 
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1 are expressed during the embryonic period, weakly detected after birth, and 
are almost absent in adulthood (Ma et al., 1993). In the mantle zone of the spinal 
cord, subunit 3 is expressed transiently during the embryonic period and 
postnatally (Ma et al., 1993). In the cerebellar cortex, subunit 1 demonstrates 
low expression in the first postnatal week, decreased expression in the second 
postnatal week and is minimally expressed in the third week (Zdilar et al., 1992). 
Peak expression of subunits 2, 3, 3, and 2 occurs between the late 
embryonic and early postnatal period (Ma et al., 1993; Zdilar et al., 1992). 
 In situ hybridization revealed a differential expression of GABAB receptor 
subtypes in the developing rat spinal cord. Both GABA subtypes were present at 
birth, but GABAB1 receptors exhibited increased expression across postnatal 
development, while GABAB2 receptors decreased in number (Sands et al., 2003). 
Expression of GABAB2 receptors was less robust than GABAB1 across all ages 
(Sands et al., 2003).  
Glutamate Receptors 
 Glutamate exerts its effects through two classes of receptors: ionotropic 
and metabotropic receptors. The three glutamate ionotropic receptors are -
amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), N-methyl-D-
aspartate (NMDA), and kainate (Roberto & Varodayan, 2017). The ionotropic 
receptors are nonselective cation channels allowing the passage of Na+ and K+ 
and, in some instances, Ca2+ (Meyer & Quenzer, 2005). AMPA receptors can be 
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found in the hippocampus, cerebral neocortex, cerebellum, retina and thalamic 
reticular nucleus, while NMDA receptors are detected in the substantia nigra, 
brain stem, and spinal cord (Gereau & Swanson, 2008). Kainate receptors are 
predominantly found in the spinal cord, but also mediate responses in the 
amygdala, thalamus, and the mossy fibers of the hippocampus (Gereau & 
Swanson, 2008) 
 Glutamate has eight metabotropic receptors (mGluR 1-8). These 
receptors are G-protein coupled and are classified into three groups: group one 
includes mGluR 1 and 5, group two consists of mGluR 2 and 3, and group three 
is made up of mGluR 4, 6, 7, and 8 (Gereau & Swanson, 2008). MGluR 1 and 5 
are coupled to Gq, and are primarily postsynaptic; whereas, mGluR 2-4, 6, and 7 
are coupled to Gi/Go and are generally presynaptic (Gereau & Swanson, 2008). 
Through their coupling to G proteins MGluR 1 and 5 increase the excitability of 
postsynaptic cells, whereas mGluR 2-4, 6, and 7, are inhibitory (Conn & Pin, 
1997).  
 Similar to the glutamate ionotropic receptors, mGluRs have a 
heterogenous distribution throughout the CNS. MGluR 1 is expressed in the 
globus pallidus, olfactory bulb, thalamus, basal ganglia, substantia nigra, 
amygdala, hypothalamus, medulla, cerebellum, and the CA1 and CA3 regions of 
the hippocampus (Catania et al., 1994; Gereau & Swanson, 2008). MGluR 2 is 
expressed in the hippocampus and thalamus. MGluR 3 is distributed in the 
retina, thalamus, basal ganglia, corpus collosum, trigeminal nerve, and spinal 
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cord (Catania et al., 1994; Gereau & Swanson, 2008). MGluR 4 has a patchy 
distribution, with receptors in the thalamus, striatum, and cortex (Catania et al., 
1994). MGluR 5 can be found in the olfactory bulb, caudate, cortex, 
hippocampus, globus pallidus, and nucleus accumbens (Catania et al., 1994; 
Gereau & Swanson, 2008). MGluR 6 has the most restrictive expression, being 
found in only the retina (Gereau & Swanson, 2008). MGluR 7 is expressed in the 
hippocampus, ventral pallidum, thalamus, hypothalamus, basal ganglia, brain 
stem, and spinal cord (Gereau & Swanson, 2008). Lastly, mGluR 8 can be found 
in the olfactory bulb, neocortex, hippocampus, amygdala and cerebellum 
(Gereau & Swanson, 2008). 
Ontogeny of Glutamate Receptors 
 AMPA receptors are not common in early embryonic days, but increase in 
numbers postnatally (Brennan, et al., 1997; Cristóvão, Oliveira, & Carvalho, 
2002), while NMDA receptors are abundant in early postnatal development and 
decrease in adulthood (Gereau & Swanson, 2008). There is a notable 
developmental shift in the expression of the glutamate metabotropic receptors. 
Catania et al. (1994) reported that mGluR1, mGluR2 and mGluR4 receptors are 
low in expression at birth, but increase gradually with maturation, while mGluR3 
and mGluR5 receptors are expressed at birth in high levels but decline with 





 Monoamines are small molecular weight neurotransmitters that mediate a 
variety of physiological and homeostatic functions (Jaber et al.,1996; Kopin, 
1968). Monoamines contain an amino group that is connected to an aromatic ring 
by a two-carbon chain (Kopin, 1968). There are different types of monoamine 
neurotransmitters: catecholamines and indolamines. Catecholamines contain a 
catechol group and a side chain amine and are derived from the amino acid 
tyrosine. This group of neurotransmitters includes DA, NE and epinephrine 
(Kopin, 1968). The indoleamine, serotonin, derives from the amino acid L-
tryptophan (Fidalgo, Ivanov, & Wood, 2013; Coulombe & Sharma, 1986). These 
monoamine neurotransmitter systems are relevant to the present study; thus, 
they will be further discussed in the sections to follow.  
The Dopamine System 
 DA was once thought of as only a precursor for epinephrine and 
norepinephrine (Goldstein, 2010; Kopin, 1968), but DA is now recognized as an 
important catecholamine neurotransmitter (Jaber et al.,1996). DA is involved in a 
variety of functions, including locomotion, emotions, memory, and 
neuroendocrine secretion (Jaber et al.,1996). DA imbalance and dysfunction are 
associated with neurological and psychiatric disorders, such as attention-deficit 
hyperactivity disorder, schizophrenia, and drug addiction (Jaber et al.,1996; 
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Kobayashi, 2001), while degeneration of DA neurons can lead to the 
neurodegenerative disorder Parkinson’s disease (Jaber et al.,1996). DA was first 
synthesized in 1910 by George Barger and James Ewen at Wellcome 
Laboratories (Goldstein, 2010). DA was identified as a neurotransmitter by Arvid 
Carlsson and Nils-Ake Hillarp in 1958 (Goldstein, 2010). 
Dopamine Synthesis, Release, and Catabolism 
 DA is synthesized in the terminal of the presynaptic neuron, in a two‐step 
process. The biosynthesis of DA begins with the conversion of L-tyrosine to L-
dihydroxyphenylalanine (L-DOPA) by the cytosolic enzyme tyrosine hydroxylase. 
In turn, L-DOPA is converted into DA by aromatic amino acid decarboxylase 
(AADC) (Fernstrom & Fernstrom, 2007; Nagatsu, Levitt, & Udenfriend, 1964). 
Tyrosine hydroxylase is the rate limiting step in the synthesis of DA and controls 
the rate of synthesis due to its availability (Fernstrom & Fernstrom, 2007). DA 
signaling and distribution are dynamically regulated by several factors. Following 
synthesis, VMAT2 transports DA from the cytoplasmic space into synaptic 
vesicles (German et al., 2015). DA is released into the synaptic cleft via calcium-
dependent exocytosis (Tritsch & Sabatini, 2012). Once released, DA can bind to 
and activate both pre- and postsynaptic DA receptors (German et al., 2015). The 
termination of DA neurotransmission is initiated by the reuptake of DA back into 
the terminal via DAT (German et al., 2015; Meiser, Weindl, & Hiller, 2013). DA 
can then be metabolized by monoamine oxidase (MAO) into 3,4-
dihydroxyphenylacetaldehyde (DOPAL) (Meiser et al., 2013). DOPAL can be 
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further oxidized into carboxylic acid 3,4-dihydroxyphenylacetic acid (DOPAC) via 
ALDH (Meiser et al., 2013). DOPAC is converted to homovanilic acid (HVA) via 
catechol-O-methyl transferase (COMT) (Meiser et al., 2013). 
Dopamine Innervation 
 In the CNS, cell bodies of DA neurons are found in the mesencephalon, 
diencephalon, olfactory bulb, and retina (Binder et al., 2001). The neuronal 
projections from these brain areas give rise to four major dopaminergic 
pathways: the nigrostriatal, mesolimbic, mesocortical, and tuberoinfundibular 
pathways. The nigrostriatal pathway originates in the substantia nigra pars 
compacta and ascends to the striatum where it terminates. The nigrostriatal 
pathway plays a crucial role in motor control, and damage to this pathway results 
in Parkinson’s disease (Binder et al., 2001). The pathway that mediates reward 
and motivation is referred to as the mesolimbic pathway, which encompasses 
neurons projecting from the ventral tegmental area to the nucleus accumbens, 
amygdala, and olfactory tubercule (Binder et al., 2001; Opland, Leinninger, & 
Myers, 2010). The mesocortical DA pathway projects from the ventral tegmental 
area to the cerebral cortex, particularly the prefrontal cortex (Compton & Hudzik, 
2015; Kobayashi, 2001). The mesocortical pathway is important for motivation, 
emotion, and memory formation (Kobayashi, 2001). The last of the major 
pathways is the tuberoinfundibular pathway. This pathway projects from the 
hypothalamus to the posterior pituitary (Kobayashi, 2001). DA neurons in the 
tuberoinfundibular pathway are involved in the development and maintenance of 
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the pituitary gland, as well as in gene expression and metabolism of pituitary 
peptide hormones (Kobayashi, 2001). 
Dopamine Receptors 
 DA receptors are members of a large G-protein coupled receptor family 
(Jaber et al.,1996; Niznik & Van Tol, 1992; Tritsch & Sabatini, 2012). The various 
actions of DA are mediated by five receptor subtypes, which are divided into two 
major subclasses: D1-like and D2-like receptors. Dopaminergic receptors are 
classified on the basis of physiological, pharmacological and biochemical criteria 
(Jaber et al., 1996; Kebabian & Calne, 1979). D1 and D5 receptors are part of the 
D1-like receptor family due to their high sequence homology (Jaber et al., 1996). 
These receptors are excitatory, because receptor activation stimulate Gs, thereby 
increasing adenylyl cyclase activity and subsequently activating cyclic adenosine 
monophosphate (cAMP) dependent protein kinases (Niznik & Van Tol, 1992). 
D1-like receptors are mostly found post-synaptically and are more abundant than 
D2-like receptors (Jaber et al., 1996). The D2-like family is made up of the D2, D3 
and D4 receptor subtypes (Gerfen et al., 1990). In contrast to D1-like receptors, 
D2-like receptors are inhibitory. D2-like receptors were first discovered in the 
pituitary gland and they inhibit adenylyl cyclase (Niznik & Van Tol, 1992; Jaber et 
al., 1996). D2-like receptors bind to the inhibitory G-proteins, Gi and Go, and 
decrease cAMP formation. While D1-like receptors are only found on the post-
synaptic side, D2-like receptors are localized both pre- and post synaptically 
(Niznik & Van Tol, 1992). 
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Ontogeny of Dopamine Receptors 
 Research on D1-like and D2-like receptors in the mammalian rat brain has 
revealed that both of these receptor subtypes are present at birth, but their 
pattern of development differs (McDougall et al., 2014; Moody & Spear, 1992; 
Rao, Molinoff, & Joyce, 1991). Throughout postnatal development the density of 
D1-like receptors is consistently higher than D2-like receptors (Gelbard et 
al.,1989; Rao et al., 1991). The density of D1-like receptors increases linearly 
from PD 1 to 10 followed by a dramatic increase in receptor density from PD 10 
to PD 16 (Rao et al.,1991). After this increase, comes a gradual decline until 
adult-like levels are reached between PD 28 and PD 40 (Andersen, 2003; 
Andersen et al., 2000). On the other hand, D2-like receptor expression increases 
linearly between the first and fourth postnatal weeks, they then peak around PD 
30 (Rao et al., 1991). Both D1 and D2-like receptors demonstrate peak 
expression at PD 40, this being the onset of puberty (Andersen et al., 2000). 
Additionally, both subtypes of DA receptors prune by PD 120 (Andersen et al., 
2000). 
Norepinephrine 
 The catecholamine NE is involved in a broad range of functions, such as 
attention, memory, mood, endocrine function, and response to stressors 
(Goldstein, 2010; Maletic et al., 2017). In 1946, Ulf von Euler was the first to 
identify NE as a neurotransmitter (Yamamoto et al., 2014). Dysfunction of NE 
systems has been linked to various psychiatric disorders, such as ADHD, 
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depression, anxiety, schizophrenia, and post-traumatic stress disorder 
(Biederman & Spencer, 1999; Koob, 1999; Yamamoto et al., 2014). 
Norepinephrine Synthesis and Inactivation 
 NE is synthesized from DA in the presence of the enzyme DA -
hydroxylase, with this conversion occuring within vesicles (Fernstrom & 
Fernstrom, 2007; Glowinski & Baldessarini, 1966; Goldstein, 2010; Kopin, 1968; 
Ressler & Nemeroff, 1999). Once released, NE can bind to pre- or postsynaptic 
receptors, or it can be removed via reuptake by its transporter protein NET 
(Goldstein, 2010; Ressler & Nemeroff, 1999; Wassall, Teramoto, & Cunnane, 
2009). NE can be metabolized in two ways, first, NE that has been transported 
back into the axon terminal is catabolized via MAO, which converts NE into either 
3,4-dihydroxyphenylglycol (DHPG) or 3,4-dihydroxymandelic acid (DHMA). 
Second, NE can go through enzymatic degradation by COMT, which catabolizes 
NE into its metabolite normetanephrine (Ressler & Nemeroff, 1999; Wassall et 
al., 2009). 
Norepinephrine Innervation 
 Noradrenergic pathways originate in the locus coeruleus (LC) and project 
to many parts of the brain, including the frontal cortex, cerebellum, amygdala, 
hippocampus, basal ganglia, thalamus, and hypothalamus (Maletic et al., 2017; 
Ressler & Nemeroff, 1999; Sara, 2009). 
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Classification of Norepinephrine Receptors 
 Adrenergic receptors are found in both the central and peripheral nervous 
system (Bylund et al., 1994). There are two types of adrenergic receptors,  and 
, both of which are G-protein coupled receptors (Bylund et al., 1994; Cotecchia 
et al.,1990; Maletic et. al., 2017). Each receptor type has its own family. The  
receptor family includes the 1 and 2 subtypes (Bylund et al., 1994), while the 
1 and 2 receptors each have three subtypes: 1A, 1B, and 1D; 2A, 2B, 
and 2C (Bylund et al., 1994; Kobilka, 2011; Maletic et al., 2017). The second 
major class of adrenergic receptors, , has three subtypes: β1, β2, and β3 
(Bylund et al., 1994; Maletic et. al., 2017). Adrenergic 1 and β receptors have a 
stimulatory effect on cAMP, while adrenergic 2 receptors have an inhibitory 
effect on cAMP signaling by interacting with the Gi/Go proteins (Happe et al., 
1999; Maletic et al., 2017; Sara, 2009).  
Ontogeny of Norepinephrine Receptors 
 Research has revealed differences in the developmental pattern of 
adrenergic receptors. 2 Adrenergic receptors in rat brain are widely expressed 
at birth, even in brain regions that have low expression in adulthood (e.g., white 
matter, cerebellum and the brainstem) (Happe et al., 2004). 2 Adrenergic 
receptors reach their peak expression in many brain regions around PD 15, while 
in other regions they mature later at PD 28 (basomedial amygdala, lateral 
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septum and hippocampal formation) (Happe et al., 1999, 2004). Unlike 2 
adrenergic receptor development, levels of β1 and β2 adrenergic receptors are 
low at PD 1 and increase over time (Pittman, Minneman, & Molinoff, 1980). In the 
cerebral cortex of the rat brain,  adrenergic receptor density increases rapidly 
between PD 7-21, after which receptor density remains constant and then begins 
to decline at PD 42 (Harden et al., 1977; Pittman et al., 1980). In the cerebellum, 
 adrenergic receptor density increases slowly and steadily from PD 5-42, and 
the density of receptors remains constant until approximately PD 180 (Pittman et 
al., 1980). 
Serotonin 
 Serotonin, also known as 5-hydroxytryptamine (5-HT), is found in both the 
CNS and peripheral nervous system. This monoamine plays a key role in sleep, 
sexual behavior, mood, and cognition (Fidalgo et al., 2013; Żmudzka et al., 
2018). The majority of 5-HT, an estimated 95%, is produced in the digestive tract 
(Fidalgo et. al., 2013; McCorvy & Roth, 2015), while the 5-HT found in the brain 
is produced by tryptophan hydroxylase 2 (TPH2) in the raphe nucleus (Muller, 
Anacker, & Veenstra-VanderWeele, 2016). The 5-HT system is linked to a variety 
of disorders, including Parkinson’s disease, Alzheimer’s disease, depression, 
anxiety, schizophrenia, obsessive-compulsive disorder, bipolar disorder, and, 
more recently, autism spectrum disorder (López-Figueroa et al., 2004; Muller et 
al., 2016; Żmudzka et al., 2018).  
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Serotonin Synthesis and Reuptake 
 Serotonin is synthesized in two steps. The initial step is the conversion of 
L-tryptophan to 5-hydroxy-L-tryptophan (5-HTP) by the rate-limiting enzyme 
tryptophan 5-hydroxylase (Fidalgo et al., 2013). Tryptophan 5-hydroxylase (Tph) 
has two isoforms: Tph1 and Tph2 (Fidalgo et al., 2013; Muller et al., 2016). The 
second and final step is the conversion of 5-HTP to 5-HT via AADC. AADC is 
also involved in DA synthesis (Fidalgo et al., 2013). 5-HT is released from its 
vesicles through Ca2+-dependent exocytosis; once released, it can bind to pre- or 
postsynaptic 5-HT receptors (Fidalgo et al., 2013; Filip & Bader, 2009). 5-HT is 
rapidly removed from the synaptic cleft by a reuptake process that involves the 5-
HT transporter (SERT) (Fidalgo et al., 2013). 5-HT is catalyzed by monoamine 
oxidase A (MAOA) to yield 5-hydroxyindoleacetic acid (5-HIAA) (Fidalgo et al., 
2013; Muller et al., 2016; Squires et al., 2007). 
Serotonin Innervation 
 The 5-HT system is widespread, with the majority of cell bodies located in 
the dorsal and median raphe nuclei of the caudal midbrain (Carolyn et al., 1998; 
Fidalgo et al., 2013). 5-HT axons project to the thalamus, hypothalamus, striatal 
regions, cortical regions, medulla, pons, midbrain, cerebellum, and spinal cord 
(Carolyn et al., 1998; Fidalgo et al., 2013). 
Classification of Serotonin Receptors 
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 5-HT has a large family of receptors, with a total of seven types (5-HT1-7) 
(Żmudzka et al., 2018). The majority of these receptors are G-protein coupled 
receptors, with the exception of 5-HT3, which is a ligand-gated ion channel (Filip 
& Bader, 2009; McCorvy & Roth, 2015). 5-HT1 and 5-HT5 receptors are couple to 
the Gi protein. The 5-HT1 receptor type has five subtypes (5-HT1A, 5-HT1B, 5-
HT1D, 5-HT1E, and 5-HT1F), while the 5-HT5 receptor has two subtypes (5-HT5A 
and 5-HT5B) (McCorvy & Roth, 2015). The protein Gq/11 is coupled to 5-HT2 
receptors, which includes three subtypes: 5-HT2A, 5-HT2B, and 5-HT2C. These 5-
HT2 receptors activate phospholipase C, thereby producing inositol triphosphate 
(IP3) and diacylglycerol (DAG), which increases intracellular calcium (McCorvy & 
Roth, 2015). The Gs coupled receptors include 5-HT4, 5-HT6, and 5-HT7. 
Stimulation of the Gs coupled receptors increases cAMP levels (McCorvy & Roth, 
2015). The 5-HT3 receptor family includes the isoforms 5-HT3A, 5-HT3B, 5-HT3C, 
5-HT3D and 5-HT3E (Filip & Bader, 2009). 
Ontogeny of the Serotonin System 
 In rats, 5-HT levels are low at birth, peak around PD 21–30 and then 
decline to adult levels (Murrin, Sanders, & Bylund, 2007). Similar to age-
dependent decreases in 5-HT levels (Fidalgo et al., 2013), there is evidence of 
altered levels of 5-HT receptors across ontogeny. In the cerebellum, 5-HT1 and 
5-HT3, receptors reach peak expression levels between PD 7 and PD 12, while 5-
HT2 receptors peak two weeks after birth and sustain maximal expression until 
ten weeks postnatally (Oostland & van Hooft, 2013). In the brain stem, 5-HT1 
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receptors are expressed at higher than adult levels at birth, but decrease to adult 
levels by PD 15 (Murrin et al., 2007). As a whole, 5-HT2 receptors exhibit peak 

















SUMMARY AND HYPOTHESIS 
 ADHD is a highly prevalent developmental disorder characterized by 
impulsiveness, inattention, and hyperactivity across multiple settings (Baumeister 
et al., 2012; Kiely, 2015; Russell, 2011). The etiology of this neurodevelopmental 
disorder is unclear, but is thought to have genetic, neurochemical, and 
environmental origins. Dysregulation of the central monoamine neurotransmitters 
has long been suspected to underlie the pathophysiology of ADHD, primarily 
because of the efficacy of AMP and MPH (Curatolo et al., 2010; Oades, 1987). In 
addition, a number of allelic variations involving the dopaminergic system, such 
as DAT, DRD4, and DRD5 are associated with a diagnosis of ADHD (Curatolo et 
al., 2010; Peadon & Elliott, 2010). More recently, prenatal exposure to alcohol 
has been strongly associated with a later diagnosis of ADHD (O’Malley & 
Nanson, 2002). 
 Interestingly, while there is a strong link between prenatal alchohol and 
ADHD, clinical observations of children with ADHD suggest that the 
neurobehavioral disorder caused by prenatal alcohol differs from idiopathic 
ADHD (Peadon & Elliot, 2010). Specifically, children exposed to prenatal alcohol 
have an earlier onset of ADHD symptoms, higher rates of inattention symptoms, 
lower rates of hyperactivity, different neuroanatomical changes, and less of a 
clinical response to MPH than AMP (Doig et al., 2008; Glass et al., 2014; O’Neill 
et al., 2019; Peadon & Elliott, 2010). These findings suggest that ADHD caused 
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by prenatal alcohol exposure may be a special subtype of ADHD or is a 
completely different disorder.  
 In summary, clinical and pre-clinical studies suggest that dopaminergic 
dysfunction and alcohol exposure both lead to ADHD-like symptoms, such as 
hyperactivity, impulsivity and deficits in executive function. While many children 
with fetal alcohol spectrum disorder (FASD) have ADHD symptoms, the 
relationship between the two is not well understood. In particular, the effects of 
pre-existing DA dysfunction in combination with early alcohol exposure is 
unknown. To gain insight on this relationship, this thesis assessed the effects of 
early alcohol exposure on normal and DA-deficient rats.  
 To this end, we measured DA content, basal and psychostimulant-induced 
locomotor activity, and passive avoidance learning in DA-deficient rats, alcohol 
exposed rats, and a combined group that consisted of rats with both a DA 
deficiency and alcohol exposure. Rats were assessed during preadolescence 
(PD 20-26), since previous reports have found more pronounced deficits during 
this age span (Barron & Riley, 1990; Dursun et al., 2006; Schneider et al., 2011). 
Due to the age of the animals, we do not expect to see sex differences. A total of 
12 groups were used in order to precisely determine whether a DA deficiency in 
combination with alcohol exposure enhances hyperactivity and impulsivity. 
 Overall, we had two primary hypotheses. First, we looked at locomotor 
hyperactivity by measuring the activity of the rats. We predicted that the alcohol 
exposed rats would display locomotor hyperactivity, because this has been 
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reported in children and in preweaning and juvenile rats after perinatal exposure 
to ethanol (Barron & Riley, 1990; Dursun et al., 2006). We predicted that the DA-
deficient rats would show more locomotor hyperactivity when compared to the 
alcohol exposed rats. This hypothesis was based on reports from clinical studies 
showing that children with prenatal alcohol exposure exhibit lower rates of 
locomotor hyperactivity than children with ADHD (Glass et al., 2014). Lastly, we 
hypothesized that the combined group would exhibit increased locomotor 
hyperactivity, relative to the other two groups. Additionally, AMP- and MPH-
induced changes in locomotion were compared. The purpose of this experiment 
was to determine whether findings using this rodent model were consistent with 
results obtained in clinical populations with this subtype of ADHD. We predicted 
that DA-deficient rats would have a similar response to AMP and MPH. We 
anticipated that the alcohol exposed group and the combined group would show 
less of a response to MPH than AMP. This hypothesis was based on clinical 
evidence demonstrating that humans exposed to alcohol at an early age 
responded better to AMP than to MPH (Peadon & Elliott, 2010). 
 Second, this thesis assessed learning impairments and impulsivity via the 
passive avoidance learning task. The passive avoidance task is used to assess 
aspects of executive function, such as learning and memory (Hausknecht et al., 
2005; Schneider et al., 2011) as well as inhibitory control (Abel, 1982; Barron & 
Riley, 1990; Bizot & Thiébot, 1996; Cronise et al., 2001; Dursun et al., 2006). In 
this task, animals learn to avoid an aversive stimulus by inhibiting a previously 
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punished response (Abdel-Mouttalib, 2015). We predicted that DA-deficient rats 
would show poor passive avoidance learning. This hypothesis was based on past 
findings demonstrating that 6-OHDA lesioned rats exhibit learning impairments in 
similar tasks (Russell, 2011; Sagvolden et al., 2005; Stanford & Tannock, 2011). 
We expected alcohol exposed rats to show more profound deficits on the passive 
avoidance task than 6-OHDA rats. This hypothesis was based on evidence from 
previous studies showing that alcohol exposure during the neonatal period 
results in a lack of response inhibition during early adolescence (Abel, 1982; 
Barron & Riley, 1990; Cronise et al., 2001; Dursun et al., 2006). Lastly, it was 
hypothesized that a 6-OHDA lesion in combination with neonatal alcohol 
treatment would result in a greater inability to withhold responding when 















 Subjects were 1,053 male and female rats (Charles River, Hollister, CA) of 
Sprague-Dawley descent. All subjects were born and raised at California State 
University, San Bernardino (CSUSB). The day of parturition was considered PD 
0. Beginning on PD 3, each rat was given a distinctive tail mark using colored 
nontoxic markers. The subjects were given unlimited access to both food and 
water throughout the study. Pups were kept with the dam until PD 26 in a 
climate-controlled vivarium maintained at 22-24°C and kept under a 12:12h 
light/dark cycle. All subjects were cared for according to the “Guide for the Care 
and Use of Laboratory Animals” (National Research Council, 2010) under a 
research protocol approved by the Institutional Animal Care and Use Committee 
of CSUSB. 
Drugs 
 Desipramine hydrochloride, 6-hydroxydopmaine (6-OHDA), 
methylphenidate, and amphetamine were obtained from Sigma-Aldrich (St. 
Louis, MO). 6-OHDA was mixed in a sterile saline solution containing 0.1% 
ascorbic acid. Methylphenidate and amphetamine were dissolved in saline at a 
volume of 2.5 ml/kg. Ethanol (Decon Labs, Inc., 100% USP certified) was mixed 
in a commercially available milk solution (Enfamil Premium Infant Formula, Mead 
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Johnson). Powder Enfamil was mixed with distilled water according to the 
manufacturer’s directions to make 60 ml each day (8.9 g powder in 60 ml of 
water). Ethanol was diluted with the milk solution to make 0.3 g/kg and 3 g/kg 
solutions and was stored in the refrigerator until used. Ethanol and milk solutions 
were given orally, at a volume of 19 ml/kg. Unused ethanol and milk solutions 
were discarded at the end of each day. 
Apparatus 
Locomotor Activity 
 Behavioral testing was done in activity monitoring chambers (26 x 26 x 41 
cm) that consist of a plastic floor, acrylic walls, and an open top. Distance 
traveled was measured. 
Passive Avoidance 
 Passive-avoidance testing occurred in clear Plexiglas shuttle boxes 
divided into two equal compartments (14 x 7 x 12cm) separated by a guillotine 
door. One of the chambers was transparent and the other was dark and opaque. 
The flooring of the boxes was composed of stainless-steels bars. A Coulbourn 
solid-state shock generator delivered a 0.5-mA pulse of distributed shock to the 




On PD 3, culled rats were given an injection of desipramine (25 mg/kg, IP) 
to preserve noradrenergic neurons. After 45 min, pups received a topical 
anesthetic (4% lidocaine solution) and were injected (IC) with 10 µL of 6-OHDA 
or vehicle at a depth of 0.4 cm using a 30-gauge needle attached to a 25 µL 
Hamilton microsyringe. The needle was inserted into the foramen magnum 
between the occipital bone and the first cervical vertebra. Following the 6-OHDA 
microinjection procedure, pups were returned to their home cages.  
Intragastric Intubation Feeding 
 Daily intragastric intubations occurred from PD 4-9. Weight was recorded 
on each day of feeding. Pups were placed on a heating pad for the duration of 
the intubation procedure. Intubations were administered using PE 10 Intramedic 
tubing connected to a syringe (1 mL with a 23-guage needle) via a small piece of 
PE 50 Intramedic tubing. The PE 10 tubing was marked prior to the start of 
intubation, in order to indicate the distance necessary to reach the stomach. Rat 
pups were held securely so their esophagus was in linear plane. The PE 10 
tubing was dipped in corn oil to ease the stress of intubation. The tubing was 
inserted so that it moved over the tongue and follows the roof of the mouth, to the 
throat, and down to the stomach. 
Dopamine Content Assay 
 On PD 21, 6-OHDA and alcohol treated animals were euthanized by rapid 
decapitation and their striatum was removed and stored for future analysis of DA 
levels. The striatum of each subject was stored at -80 °C. During the DA content 
 46 
assay, frozen tissue was sonicated and dissolved in 10 volumes of 0.1 N HClO4 
and centrifuged at 20,000 x g for 30 min at 4 °C. Resulting supernatant was 
filtered through a 0.22 µm centrifugation apparatus at 2,000 x g for 5 min at 4 °C. 
The resulting extracts (20 µL) were assayed for DA content using high 
performance liquid chromatography with electrochemical detection (Coulochem 
II; ESA). The mobile phase was comprised of 75 mM NaH2PO4, 1.4 mM 1-octane 
sulfonic acid, 10 mM EDTA, and 10% acetonitrile [(pH 3.0) MD-TM Mobile 
Phase; ESA] and pumped at a rate of 0.5 mL per min.  
Experiment 1: Comparison of Dopamine Depletion, Early Alcohol Exposure, or 
Combined Treatment on Basal and Psychostimulant-Induced Locomotor Activity 
 Male and female animals were randomly assigned to one of 36 groups (n= 
9). The first independent variable was lesion, with three levels (no lesion, sham, 
or 6-OHDA). The second independent variable was intubation, with four levels 
(no intubation, 0, 0.3, or 3 g/kg ethanol). The third independent variable was 
psychostimulant treatment with three levels (saline, methylphenidate or 
amphetamine).  
On PD 19, male and female rats were habituated to the locomotor activity 
chambers and then returned to their home cage. The following day (PD 20) male 
and female rats were injected intraperitoneally (ip) with saline, methylphenidate 
(2.5 mg/kg) or amphetamine (1 mg/kg).  On both days, locomotor activity was 





Table 1. Design of Experiment 1 
LESION INTUBATION DRUG 
No lesion No Intubation Saline, MPH, or AMP 
No lesion 0 g/kg ethanol Saline, MPH, or AMP 
No lesion 0.3 g/kg ethanol Saline, MPH, or AMP 
No lesion 3 g/kg ethanol Saline, MPH, or AMP 
Sham No Intubation Saline, MPH, or AMP 
Sham 0 g/kg ethanol Saline, MPH, or AMP 
Sham 0.3 g/kg ethanol Saline, MPH, or AMP 
Sham 3 g/kg ethanol Saline, MPH, or AMP 
6-OHDA No Intubation Saline, MPH, or AMP 
6-OHDA 0 g/kg ethanol Saline, MPH, or AMP 
6-OHDA 0.3 g/kg ethanol Saline, MPH, or AMP 
6-OHDA 3 g/kg ethanol Saline, MPH, or AMP 
 
 
Experiment 2: Comparison of Dopamine Depletion, Early Alcohol Exposure, or 
Combined Treatment on Passive Avoidance Learning 
 Male and female animals were randomly assigned to one of twelve groups 
(n= 10). On PD 23, subjects began training on a step-through passive avoidance 
task. Acquisition occurred on PD 23 and retention of the passive avoidance was 
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assessed on the following three days. On the acquisition day, the rat was placed 
in the clear illuminated compartment with the guillotine door closed. After 30 s, 
the door opened. Movement to the adjoining chamber resulted in closure of the 
dividing door and delivery of a brief (3 s) foot shock (0.5-mA). Latency for the rat 
to cross from the clear to the dark compartment was recorded. After 30 s, the rat 
was removed from the testing chamber and returned to the home cage. 
Retention was assessed after an interval of 24 h (PD 24), 48 h (PD 25), and 72 h 
(PD 26). Specifically, rats were placed in the clear illuminated compartment with 
the door open and the latency to leave the illuminated chamber was measured. 
No shock was administered on retention trials. Retention trials were discontinued 
after 600 s if the rat did not move into the dark compartment. 
 
 
Table 2. Design of Experiment 2 
LESION INTUBATION 
No lesion No Intubation 
No lesion 0 g/kg ethanol 
No lesion 0.3 g/kg ethanol 
No lesion 3 g/kg ethanol 
Sham No Intubation 
Sham 0 g/kg ethanol 
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Sham 0.3 g/kg ethanol 
Sham 3 g/kg ethanol 
6-OHDA No Intubation 
6-OHDA 0 g/kg ethanol 
6-OHDA 0.3 g/kg ethanol 






 DA and DOPAC were analyzed by separate 3 x 4 x 2 (lesion x alcohol x 
sex) three-way ANOVAs. Post hoc analysis of the neurochemical data was made 
using Tukey tests (p <.05). 
Experiment 1 
 Basal locomotor activity (distance traveled) was analyzed by a 2 x 3 x 4 
(sex x lesion x alcohol) three-way ANOVA. Significant higher-order interactions 
were further analyzed using one- or two- way ANOVAs. Post hoc analysis of the 
behavioral data was made using Tukey tests (p <.05) 
 Psychostimulant-induced locomotor activity (distance traveled) was 
analyzed by a 2 x 3 x 4 x 3 (sex x lesion x alcohol x drug) four-way ANOVA. 
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Significant higher-order interactions were further analyzed using one- or two- way 
ANOVAs. Post hoc analysis of the behavioral data was made using Tukey tests 
(p <.05). Litter effects were controlled by assigning no more than one rat from 
each litter to a particular group. 
Experiment 2 
 Passive avoidance data were analyzed using a 2 x 3 x 4 x 4 (sex x lesion 
× alcohol x day) mixed factors ANOVA, with sex, lesion, and alcohol being 
between-subject factors and day being a within-subject repeated measures 
factor. Mauchly’s test was used to detect violations of the sphericity assumption. 
When violations of sphericity were detected, the Huynh-Feldt Epsilon statistic 
was used to make corrections. When appropriate, post-hoc analyses were 
















 On the habituation day, lesion condition significantly impacted locomotor 
activity because rats that received 6-OHDA lesions had larger distance traveled 
scores than rats in the sham or no lesion groups [Lesion main effect, F(2,614) = 
57.38, p<.001] (see Figure 1). The 6-OHDA lesion (M = 6035.63, SEM = 186.72) 
significantly increased the distance traveled scores of rats when compared to 
sham lesion (M = 3592.21, SEM = 181.34) and no lesion rats (M = 3629.98, SEM 
= 180.53). Neither sex nor early exposure to alcohol altered locomotor activity 
(see Figure 2). In addition, sex, lesion and alcohol did not interact to affect basal 
locomotor activity. 
 Further analyses showed that there were no significant differences 
between the two lesion control groups (i.e., sham and no lesion) and the two 
alcohol control groups (no intubation and only milk).  Thus, the separate control 
groups were combined to form a single lesion control group and a single alcohol 
control group for subsequent analyses.    
Test Day 
 On the test day, locomotor activity was greatly increased by the 
psychostimulants (amphetamine or methylphenidate) [Drug main effect, F(2,557) 
= 410.52, p<.001 (see Figure 3).  The effects of amphetamine (1mg/kg) (M = 
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20661.70, SEM = 474.40) and methylphenidate (2.5 mg/kg) (M = 22169.99, SEM 
= 487.52) did not significantly differ from one another. The effects of saline (M = 
4736.14, SEM = 473.77) were significantly different than that of amphetamine 
and methylphenidate. 
The effect of psychostimulant administration on locomotor activity was 
altered by sex, lesion condition, and alcohol exposure [Sex × Lesion × Alcohol × 
Drug interaction, F(4,593) = 2.46, p<.05]. To interpret the meaning of the four-
way interaction, separate ANOVAs were conducted for each drug treatment. 
 Saline Treatment.  Similar to the habituation day, rats given 6-OHDA 
lesions exhibited greater locomotor activity than lesion controls [Lesion main 
effect, F(1,202) = 31.55, p<.001] (see Figure 4). The 6-OHDA lesion (M = 
6518.14, SEM = 3831.95) significantly increased the distance traveled scores of 
rats when compared to lesion controls (M = 3818.7007, SEM = 2590.26). This 
effect of lesion was affected by both sex and alcohol condition [Sex × Lesion × 
Alcohol interaction, F(2,202) = 3.40, p<.05] (see Figure 4).  Specifically, when 
only female rats were analyzed, non-lesioned rats treated with the low dose of 
alcohol (0.3 g/kg), had increased distance traveled scores as compared to 
female rats in the alcohol control or high dose alcohol groups, [Alcohol effect, 
F(2,72) = 10.64, p<.001, and Tukey tests, p<.05] (see Figure 4). 
 Amphetamine Treatment.  Sex significantly impacted the rat’s response to 
AMP [Sex main effect, F(1,201) = 4.95, p<.05] (see Figure 5). Male rats (M = 
22341.32, SEM = 900.62) given AMP had greater distance traveled scores than 
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female rats (M = 19502.98, SEM = 904.38). In contrast to my predictions, the 
effect of sex was not significantly affected by lesion or alcohol condition [Sex × 
Lesion × Alcohol interaction, F(2,201) = 2.70, p=.07, ns] (see Figure 5). 
 Methylphenidate Treatment. Male rats (M = 23154.18, SEM = 872.46) that 
received MPH on the test day had higher levels of locomotor activity than female 
rats (M = 21233.07, SEM = 749.38), [Sex main effect, F(1,190) = 6.77, p<.05] 
(see Figure 6). This increased locomotor activity in male rats was most 
pronounced in rats that received 6-OHDA lesions [Sex × Lesion interaction, 
F(1,190) = 4.16, p<.05] (see Figure 6), because further analyses showed MPH-
treated male rats with 6-OHDA lesions had greater distance traveled scores than 
MPH-treated female rats with 6-OHDA lesions [Sex main effect, F(1,57) = 6.99, 
p<.05] (see Figure 6). 
Monoamine Assays  
 DA Levels. As expected, there were significant differences in striatal DA 
levels as a result of 6-OHDA lesions [Lesion main effect, F(2,190) = 375.23, 
p<.001 and Tukey tests p<.001] (see Figure 7).  Specifically, the 6-OHDA lesion 
group (M = 1.68, SEM = .20) had significantly lower levels of DA than both the 
sham lesion (M = 6.95, SEM = .17) and the no lesion group (M = 6.82, SEM = 
.15). Alcohol did not affect DA levels, [Alcohol main effect, F(3,190) = 2.59, 
p=0.054, ns] (see Figure 7). While not significant, the low dose of alcohol (0.3 
mg/kg) appeared to produce a small reduction in DA levels, when compared to 
the control and high alcohol groups. 
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 DOPAC Levels. Rats given 6-OHDA lesions (M = .39, SEM = .03) had 
reduced striatal DOPAC levels when compared to the sham (M = 1.36, SEM = 
.05) and no lesion group (M = 1.29, SEM = .04), [Lesion main effect, F(2,190) = 
208.58, p<.001, and Tukey tests, p<.001] (see Figure 8). Alcohol treatment did 
not significantly impact striatal DOPAC levels [p=.29]. 
Experiment Two 
Passive Avoidance Training  
 All rats responded similarly on the conditioning trial, since the time to enter 
the dark chamber was unaffected by sex, lesion treatment or alcohol exposure. 
Furthermore, rats in all groups had significantly greater latencies to enter the 
dark chamber after the conditioning trial, thus demonstrating that the rats learned 
and retained the passive avoidance task on all four retention test days [Day main 
effect, F(3, 621) = 53.719, p<0.001] (see Figure 9).  Because the latency times 
were significantly affected by day, further analyses were conducted separately 
for each test day. 
 Test Day 1. On the first test day, step-through latencies were significantly 
shorter for rats lesioned with 6-OHDA (M = 72.07, SEM = 12.72), as compared to 
the no lesion control group (M = 191.13, SEM = 21.75), [Lesion main effect, F(2, 
207) = 10.357, p<0.001, Tukey tests, p<0.05] (see Figure 10). Sham lesioned 
rats (M = 119.80, SEM = 17.66) had marginally longer latencies when compared 
to 6-OHDA lesioned rats, but this difference was not significant. There was also a 
non-significant trend for both sex and alcohol to alter the effects of lesion on 
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step-through latencies [Sex × Lesion × Alcohol interaction, F(6, 207) = 2.108, 
p=0.054]. Specifically, alcohol-exposed male rats in the no lesion condition had 
shorter step-through latencies than non-exposed rats in the same lesion 
condition.   
 Test Day 2. Similar to the first test day, 6-OHDA lesioned rats (M = 78.44, 
SEM = 15.45) on Test Day 2 had shorter step-through latencies when compared 
to rats in the control lesion groups, no lesion (M = 184.86, SEM = 24.43) and 
sham lesion (M = 142.23, SEM = 20.95), [Lesion main effect, F(2, 207) = 6.609, 
p<0.01, Tukey tests, p<0.05] (see Figure 11). Alcohol exposure and sex did not 
affect step-through latencies on Test Day 2.   
 Test Day 3. On the last test day, once again the 6-OHDA lesion rats (M = 
58.49, SEM = 12.74) showed a decrease in latency to move to the dark chamber 
when compared to both no lesion (M = 175.01, SEM = 24.35) and sham lesion 
(M = 141.00, SEM = 23.47) controls [Lesion main effect, F(2, 207) = 8.484, 
p<0.001, Tukey tests, p<0.05] (see Figure 12). This difference in step-through 
latencies in the lesion condition was moderated by alcohol treatment [Lesion × 
Alcohol interaction, F(6, 209) = 2.648, p<0.05] (see Figure 12). Specifically, both 
male and female rats in the no lesion condition exposed to the high dose of 
alcohol (3 g/kg) had shorter latencies than rats in the same lesion condition 
exposed to milk only (0 g/kg) [Tukey tests, p<0.05]. Moreover, males in the sham 
condition that were exposed to a high dose of alcohol (3 g/kg) had longer step-
through latencies than male rats in the same lesion condition but not exposed to 
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alcohol [Sex × Lesion × Alcohol interaction, F(6, 207) = 2.154, p<0.05, Tukey 















Figure 1. Experiment 1 Habituation Day 
Mean distance traveled scores (± SEM) of male and female rat pups on the 
habituation day (PD 19).  On PD 3, rats were either untreated (no lesion), given a 
sham lesion (sham), or lesioned with 6-ODHA infusions (100 μg/10 μl, ic). 
Starting on PD 4, rats received alcohol infusions (0, 0.3 or 3 g/kg) daily or were 
unhandled (no intubation) until PD 9.  Distance traveled testing occurred on PD 















































Figure 2. Experiment 1 Habituation Day 
Mean distance traveled scores (± SEM) of male and female rat pups on the 
habituation day (PD 19). On PD 3, rats were either untreated (no lesion), given a 
sham lesion (sham), or lesioned with 6-ODHA infusions (100 μg/10 μl, ic). 
Starting on PD 4, rats also received ethanol infusions (0, 0.3 or 3 g/kg) daily or 









































Figure 3. Experiment 1 Test Day 
Mean distance traveled scores (± SEM) of male and female rat pups on the test 
day (PD 20).  On PD 3, Rats were either untreated (no lesion), given a sham 
lesion (sham), or lesioned with 6-ODHA infusions (100 μg/10 μl, ic). Starting on 
PD 4, rats also received alcohol infusions (0, 0.3 or 3 g/kg) daily or were 
unhandled (no intubation) until PD 9. On the test day, rats received saline, AMP 
(1 mg/kg, ip), or MPH (2.5 mg/kg, ip) before distance traveled testing. 







































Figure 4. Experiment 1 Test Day 
Mean distance traveled scores (± SEM) of male and female rat pups in the saline 
condition on the test day (PD 20). On PD 3, rats were either untreated (no 
lesion), given a sham lesion (sham), or lesioned with 6-ODHA infusions (100 
μg/10 μl, ic). From PD 4-9, rats were exposed to ethanol (0, 0.3, or 3 g/kg) daily 
or were unhandled (no intubation). On PD 20, rats had been injected with saline, 
AMP (1 mg/kg, ip), or MPH (2.5 mg/kg, ip) before being placed in the activity 
chambers. ‘a’ Indicates a significant difference from the control lesion rats (i.e., 
no lesion and sham). ‘b’ Indicates a significant difference from the no alcohol and 



























































Figure 5. Experiment 1 Test Day 
Mean distance traveled scores (± SEM) of rats in the amphetamine condition on 
test day (PD 20). On PD 3, male and female rats were untreated (no lesion), 
given a sham lesion (sham), or lesioned with 6-ODHA infusions (100 μg/10 μl, 
ic). From PD 4-9, rats were exposed to ethanol (0, 0.3, or 3 g/kg) daily or were 
unhandled (no intubation). On PD 20, rats were injected with saline, AMP (1 



















































Figure 6. Experiment 1 Test Day 
Mean distance traveled scores (± SEM) of male and female rat pups in the MPH 
condition on the test day (PD 20). On PD 3, rats were either untreated (no 
lesion), given a sham lesion (sham), or lesioned with 6-ODHA infusions (100 
μg/10 μl, ic). From PD 4-9, rats were exposed to ethanol (0, 0.3, or 3 g/kg) daily 
or were unhandled (no intubation). On PD 20, rats were injected with saline, AMP 
(1 mg/kg, ip), or MPH (2.5 mg/kg, ip) before being placed in the activity chambers 
‘a’ Indicates a significant difference from female 6-OHDA rats treated with MPH 























































Figure 7. Striatal DA Content 
Mean (±SEM) striatal DA content of male and female rat pups on PD 21. On PD 
3, rats were either untreated (no lesion), given a sham lesion (sham), or lesioned 
with 6-ODHA infusions (100 μg/10 μl, ic). From PD 4-9, rats were exposed to 
ethanol (0, 0.3, or 3 g/kg) daily or were unhandled (no intubation).   




















































Figure 8. Striatal DOPAC Content 
Mean (±SEM) striatal DOPAC content of male and female rat pups on PD 21. On 
PD 3, rats were untreated (no lesion), given a sham lesion (sham), or lesioned 
with 6-ODHA infusions (100 μg/10 μl, ic). Starting on PD 4, rats received ethanol 
infusions (0, 0.3 or 3 g/kg) daily or were unhandled (no intubation) until PD 9. 













































Figure 9. Step-through Latency on Conditioning Day 
Mean step-through latency (± SEM) of male and female rat pups on the 
conditioning day (PD 23) and test days 1-3 (PD 24-26). On PD 3, rats were either 
untreated (no lesion), given a sham lesion (sham), or lesioned with 6-ODHA 
infusions (100 μg/10 μl, ic). From PD 4-9, rats were exposed to alcohol (0, 0.3, or 
3 g/kg) daily or were unhandled (no intubation). On PD 23, rats were conditioned 
by receiving a shock when they entered the dark chamber. Retention was tested 
for three consecutive days (PD 24-26). ‘a’ Indicates a significant difference 












































Figure 10. Step-through Latency on Test Day 1 
Mean step-through latency (± SEM) of male and female rat pups on test day 1 
(PD 24). On PD 3, rats were either untreated (no lesion), given a sham lesion 
(sham), or lesioned with 6-ODHA infusions (100 μg/10 μl, ic). From PD 4-9, rats 
were exposed to alcohol (0, 0.3, or 3 g/kg) daily or were unhandled (no 
intubation). On PD 23, rats were conditioned by receiving a shock when they 
entered the dark chamber. Retention was tested for three consecutive days (PD 



































































Figure 11. Step-through Latency on Test Day 2 
Mean step-through latency (± SEM) of male and female rat pups on test day 2 
(PD 25). On PD 3, rats were either untreated (no lesion), given a sham lesion 
(sham), or lesioned with 6-ODHA infusions (100 μg/10 μl, ic). From PD 4-9, rats 
were exposed to alcohol (0, 0.3, or 3 g/kg) daily or were unhandled (no 
intubation). On PD 23, rats were conditioned by receiving a shock when they 
entered the dark chamber. Retention was tested for three consecutive days (PD 





































































Figure 12. Step-through Latency on Test Day 3 
Mean step-through latency (± SEM) of male and female rat pups on test day 3 
(PD 26). On PD 3, rats were either untreated (no lesion), given a sham lesion 
(sham), or lesioned with 6-ODHA infusions (100 μg/10 μl, ic). From PD 4-9, rats 
were exposed to alcohol (0, 0.3, or 3 g/kg) daily or were unhandled (no 
intubation). On PD 23, rats were conditioned by receiving a shock when they 
entered the dark chamber. Retention was tested for three consecutive days (PD 
24-26). ‘a’ Indicates a significant difference relative to the no lesion and sham 
group. ‘b’ Indicates a significant difference from the no alcohol group (0 g/kg). ‘c’ 









































































Figure 13. Step-through Latency by Lesion 
Mean step-through latency (± SEM) of 6-OHDA lesioned male and female rat 
pups on the conditioning day (PD 23) and test days 1-3 (PD 24-26). On PD 3, 
rats were either untreated (no lesion), given a sham lesion (sham), or lesioned 
with 6-ODHA infusions (100 μg/10 μl, ic). From PD 4-9, rats were exposed to 
alcohol (0, 0.3, or 3 g/kg) daily or were unhandled (no intubation). On PD 23, rats 
were conditioned by receiving a shock when they entered the dark chamber. 
Retention was tested for three consecutive days (PD 24-26). ‘a’ Indicates a 
significant difference relative to test days (1-3). ‘b’ Indicates a significant 

















































 The present thesis examined the individual and combined ability of 
neonatal 6-OHDA lesions and early alcohol exposure to induce ADHD-like 
symptoms in preweanling rats. In the first experiment, we assessed the 
aforementioned treatments on basal and psychostimulant-induced locomotor 
activity.  We had three hypotheses about the effects of our treatment conditions 
on basal locomotion. First, we predicted that alcohol exposed rats, similar to the 
DA-deficient rats, would display an increase in locomotor activity, because rats 
treated prenatally with alcohol show higher activity than control rats (Barron & 
Riley, 1990; Dursun et al., 2006; Hausknecht et al., 2005). Second, we 
hypothesized that alcohol exposed rats would exhibit less locomotor activity than 
DA-deficient rats. This prediction was based on past research demonstrating that 
children with prenatal alcohol exposure exhibit less hyperactivity than children 
with ADHD (Glass et al., 2014). Lastly, we hypothesized that rats given the 
combined treatment would exhibit greater locomotor hyperactivity than the other 
two groups. Additionally, we made predictions about differential responses to 
psychostimulant administration after DA depletion and alcohol exposure in rats. 
Specifically, we hypothesized that DA-deficient rats would have similar reduced 
responses to both AMP and MPH, but that both the alcohol exposed and 
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combined group would show less of a response to AMP than to MPH, this 
prediction was based on clinical literature (Peadon & Elliott, 2010). 
 In the second experiment, we assessed the effects of neonatal 6-OHDA 
lesions and early alcohol exposure in combination and individually on passive 
avoidance learning. We predicted that DA-deficient rats would perform worse 
than lesion controls on the passive avoidance task in concordance with past 
studies using 6-OHDA lesioned rats (Russell, 2011; Sagvolden et al., 2005; 
Stanford & Tannock, 2011). It was also predicted that alcohol exposed rats would 
show a more profound deficit on the passive avoidance task when compared to 
6-OHDA lesioned rats. This hypothesis was based on past research 
demonstrating that alcohol exposure results in a lack of response inhibition (Abel, 
1982; Barron & Riley, 1990; Cronise et al., 2001; Dursun et al., 2006). Lastly, it 
was hypothesized that combined treatment would produce the greatest deficit on 
this task.  
Basal Locomotion 
 The locomotor data revealed that the 6-OHDA lesion resulted in greater 
distance traveled in both male and female rats. Additionally, the low dose of 
alcohol increased locomotor activity in female rats after habituation to the 
chamber. In contrast to our predictions, the combined effects of lesion and 
alcohol did not result in any significant increases in locomotor activity. 
 It is well established that 6-OHDA lesions result in locomotor hyperactivity 
in rats (Russell, 2011; Sagvolden et al., 2005; Stanford & Tannock, 2011). Thus, 
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the present findings were not unexpected because both male and female rats 
lesioned with 6-OHDA had greater distance traveled scores than lesion controls.  
 On the test day, non-lesioned female rats exposed to the low dose (0.3 
g/kg), but not the high dose (3 g/kg), of alcohol, exhibited an increase in 
locomotor activity. This finding is novel, as the dose range in alcohol exposure 
studies typically falls between 1 and 6 g/kg (Brocardo et al., 2012; Hamilton et 
al., 2011; Hausknecht et al., 2017; Juárez & Guerrero-Álvarez, 2015; Patten et 
al., 2014; Vaglenova & Petkov, 1998). To our knowledge, no published studies 
report alterations in locomotor activity after low dose alcohol treatment. Data on 
the effects of early alcohol exposure on locomotor activity is limited and the data 
that do exist provide mixed results. For example, some studies report higher 
locomotor activity after moderate-dose alcohol exposure (Juárez & Guerrero-
Álvarez, 2015), while other studies do not find changes in locomotion (Atalar et 
al., 2016; Dursun et al., 2006). The present findings suggest that low-dose 
alcohol exposure during the postnatal period may have more impact on activity 
levels than higher doses. 
Psychostimulant-Induced Locomotion 
Overall, treatment with AMP (1 mg/kg) and MPH (2.5 mg/kg) produced 
nearly identical levels of locomotor activity. These findings are consistent with our 
hypothesis that rats would have a similar response to AMP and MPH. It was also 
hypothesized that psychostimulant treatment would reduce locomotor 
hyperactivity in the alcohol exposed rats and in the combined group; however, 
 73 
our results did not support this hypothesis. Overall, alcohol treatment did not 
differentially alter locomotor activity on test day, yet sex and dopamine depletion 
did alter the response to the two drugs. 
Amphetamine administration produced more locomotor activity in male 
rats than female rats. Although not statistically significant, rats exposed to alcohol 
showed a trend towards an increased locomotor activity on the test day when 
compared to the habituation day. Currently, only a few studies have measured 
the effects of psychostimulants on alcohol exposed rats and those studies report 
mixed results. One study reported that treatment with AMP resulted in no 
differential effect on hyperactivity (Bond, 1985), while another study reported an 
increase in activity following AMP treatment (Blanchard, Hannigan, & Riley, 
1987). These findings suggest that AMP may enhance activity in alcohol-treated 
rats. 
Similar to the findings with AMP, male rats treated with MPH were more 
active than female rats.  6-OHDA depletion of dopamine enhanced this 
difference, as MPH-treated male lesioned rats were more active than MPH-
treated female lesioned rats.  Alcohol exposure did not significantly alter 
locomotor activity in MPH-treated rats; however, when compared to the 
habituation day, there was an increase in MPH-induced locomotor activity. 
Consistent with our findings, Abel (1993), reported that MPH treatment enhances 
the locomotor activity of alcohol exposed rats. Conversely, Juárez and Guerrero-
Álvarez (2015) report that MPH has no effect on hyperactivity. Taken together 
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these findings suggest that treatment with MPH may not be effective at reducing 
hyperactivity in alcohol treated rats. 
 Our hypothesis that the alcohol exposed group and the combined group 
would show a lessened response to MPH, relative to AMP, was not supported.  
These findings contrast with clinical evidence showing that humans exposed to 
alcohol at an early age respond better to AMP than to MPH (Peadon & Elliott, 
2010).  
Monoamine Assays 
Because decreases in DA content are reliably associated with ADHD as 
well as deficits in learning and memory, we hypothesized that alcohol exposure 
would induce declines in DA levels similar to 6-OHDA lesions (Jaber et al.,1996; 
Kobayashi, 2001).  However, our hypothesis was not supported because alcohol 
treated rats did not exhibit a decline in DA or DOPAC levels.  In contrast, 6-
OHDA lesions resulted in the expected decrease in DA and DOPAC levels in 
preweanling rats (Stanford & Tannock, 2011).  In brief, the 6-OHDA lesion 
reliably caused a significant decrease in DA and DOPAC levels, whereas the 
alcohol treatment did not cause a reduction. 
Passive Avoidance 
 Consistent with past studies, decreasing DA content with 6-OHDA lesions 
resulted in impaired performance on the learning task.  Specifically, 6-OHDA 
lesioned male and female rats had significantly shorter latencies when compared 
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to control rats on the step-through passive avoidance task, suggesting that the 6-
OHDA lesion had an impact on learning inhibitory control and memory.  While 6-
OHDA lesions impair performance on some tasks, only one other study reported 
that 6-OHDA lesioned rats exhibited deficits on the passive avoidance task 
(Pearson et al., 1980). Like us, Pearson et al. (1980) injected their pups with 
desipramine prior to lesioning with 6-OHDA and their injection volumes and age 
(PD 27) were similar to our own (Pearson et al., 1980). In contrast several other 
studies found that 6-OHDA lesions did not affect passive avoidance performance 
(Anderson et al., 1986; Cooper, 1973; Takasuna & Iwasaki, 1996); however, 
there were clear methodological differences that could account for the disparate 
results, including the dose of 6-OHDA used and age at testing.  The current 
study used a modest dose of 6-OHDA (100 μg/10 μl), while Cooper (1973) used 
twice this dose (240 μg) and also tested the rats at a younger age (PD 14). 
Takasuna and Iwasaki (1996) also used a low dose of 6-OHDA but tested the 
rats at PD 90. Future research is necessary to determine the relationship 
between 6-OHDA dose and age at testing on passive avoidance learning.  
 The results relating to the effects of alcohol exposure on passive 
avoidance learning were in partial support of our hypothesis. Specifically, when 
given a high dose of alcohol (3 g/kg) both non-lesioned male and female rats as 
well as sham lesioned male rats exhibited memory deficits on the third retention 
day. Interestingly alcohol did not affect the performance of non-lesioned or sham 
lesioned rats on the earlier test days.  
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 The current study demonstrated memory deficits in both sexes, while a 
past investigations only saw deficits in female rats (Abel,1982; Barron & Riley, 
1990). The Barron and Riley (1990) study, like the current investigation, 
specifically assessed sex differences, but had a number of important 
methodological differences from our study. First, was the mode of alcohol 
exposure.  The current study used intragastric intubation, while Barron and Riley 
(1990) used artificial rearing. Second, the alcohol concentration differed.  Our 
study used a dose of 3 g/kg, while their dose (6.0 g/kg) was twice the amount of 
the current study (Barron & Riley, 1990). It is unclear whether these 
methodological differences played a role in the differing results found in the 
present thesis and in the study of Barron and Riley (1990), but direct 
comparisons between the two modes of exposure and level of alcohol are 
warranted and could provide clarity on this issue. 
 Taken together, findings from the present thesis and past research 
demonstrate that alcohol exposure during the neonatal period does affect 
performance in male and female rats on the passive avoidance task. Further 
research will be needed to determine how this alcohol effect differs by sex and 
dose. Researchers may consider using doses between 3.0 to 6.0 g/kg, because 
evidence suggests that during the neonatal period a higher dose of alcohol is 
more effective in causing impairments in behavioral measures (Brocardo et al., 




 The major findings from the present thesis are fourfold: 1) 6-OHDA lesions 
resulted in both a DA-deficiency and hyperactivity in male and female rats. 
Moreover, psychostimulant administration increased locomotor activity instead of 
attenuating this behavior. 6-OHDA lesions also resulted in an impairment in 
inhibitory control and memory on the passive avoidance task. 2) Exposure to a 
low dose of alcohol (0.3 g/kg) did not alter DA levels, but did cause an increase 
in locomotor activity in female rats. 3) Exposure to a high dose of alcohol (3 g/kg) 
did not alter DA levels or acquisition of a passive avoidance task, but did impair 
memory. 4) Lastly, the combined effects of 6-OHDA lesions and alcohol did not 
have an additive or synergistic effect on locomotor activity, DA depletion, or 
passive avoidance performance. Taken together findings from the present thesis 
and past research suggest that neonatal alcohol exposure can produce 
hyperactivity and deficits in memory, but this effect differs by sex, time of 
exposure, as well as a dose of alcohol. Additionally, the neurochemistry findings 
suggest that DA system dysfunction may not be related to the ADHD-like 
symptoms observed in alcohol-treated rats. 
 Because the results of previous preclinical work are inconsistent, more 
research needs to be conducted in this area. Researchers may consider 
investigating sex differences using various behavioral procedures and alcohol 
concentrations as there is very limited data on early alcohol exposure and ADHD. 
Future research on the effects of alcohol should also investigate the 
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noradrenergic system as our study was not able to detect a dysfunction in the DA 
system and a recent study found that atomoxetine was effective at reducing the 
ADHD-like symptoms seen in alcohol treated rats (Juárez & Guerrero-Álvarez, 
2015). 
 In conclusion, the current study provides evidence that low doses of 
alcohol can have long lasting effects. This information is important as there has 
been a substantial increase in alcohol consumption in women of childbearing age 
as gender roles have changed (Tan et al., 2015). The results from this study may 
be informative for pregnant women who consider low to moderate doses of 
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